Agile Therapeutics INC: directors' dealings · United States · SEC (Form 4)

About Agile Therapeutics INC

Agile Therapeutics Inc. (ticker AGRX) was a U.S.-based women’s healthcare company focused primarily on contraception, with its core franchise built around Twirla®, a once-weekly prescription contraceptive patch. The company was incorporated in Delaware on December 22, 1997, and historically operated from Princeton, New Jersey, United States. In its SEC filings, Agile described itself as a women’s healthcare company dedicated to addressing unmet needs in women’s health, with a particular emphasis on a non-daily hormonal contraceptive option. The business model combined clinical development, regulatory execution, commercialization, and payer-access work around a single lead product. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1261249/000155837024004262/agrx-20231231x10k.htm)) Twirla was Agile’s first and only approved product. The patch received FDA approval in February 2020 and was launched commercially in December 2020. Agile’s strategy centered on improving reimbursement, widening access through pharmacies and telehealth channels, and targeting obstetrician-gynecologists and women of reproductive age in the United States. The company said it focused its promotional effort on select high-potential U.S. states and used a lean sales-and-marketing footprint supported by third-party commercial partners. That made Agile a highly concentrated commercial story: upside depended on adoption of one product, while downside risk reflected payer pressure, competition, and the operational challenges typical of small-cap specialty pharma companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1261249/000155837024004262/agrx-20231231x10k.htm)) A major recent development was the company’s sale to Insud Pharma, a Spanish pharmaceutical group, through Insud’s U.S. subsidiary Exeltis USA. Agile announced the definitive merger agreement in June 2024 and completed the transaction on August 26, 2024. Under the deal, holders of Agile common stock were entitled to receive $1.52 per share in cash, and the company ceased to be listed on public markets after closing. Earlier in 2024, Agile had also announced its delisting from Nasdaq and moved to OTC trading before the merger closed, underscoring the company’s weakening public-market profile and the strategic logic of a takeout. ([ir.agiletherapeutics.com](https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-inc-announces-definitive-merger-agreement?utm_source=openai)) For international investors, the key takeaway is that AGRX was once a Nasdaq-listed U.S. women’s health specialist, but it is no longer a normal listed equity story. Its competitive position was narrow but clinically relevant: a differentiated transdermal contraceptive patch in a market dominated by larger pharmaceutical peers with broader product portfolios and stronger commercial infrastructure. Agile’s longer-term value proposition depended less on geographic scale than on access, reimbursement, and successful niche execution in the United States. After the Insud transaction, the company’s public-market relevance became mainly historical rather than ongoing. ([ir.agiletherapeutics.com](https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-inc-announces-completion-acquisition-insud?utm_source=openai))